journal
https://read.qxmd.com/read/38546375/a-phase-2-trial-of-orelabrutinib-showing-promising-efficacy-and-safety-in-patients-with-persistent-or-chronic-primary-immune-thrombocytopenia
#1
LETTER
Shi Yan, Hu Zhou, Ruibin Huang, Fang Wang, Heng Mei, Lie Lin, Jingming Guo, Xin Zhou, Zhenyu Li, Yaorong Liu, Sichen Li, Wei Zhou, Yu Hou, Ming Hou
No abstract text is available yet for this article.
March 28, 2024: American Journal of Hematology
https://read.qxmd.com/read/38546372/the-presence-of-additional-cytogenetic-abnormalities-acas-or-philadelphia-chromosome-variants-do-not-adversely-affect-the-achievement-of-treatment-free-remission-in-chronic-myeloid-leukemia
#2
LETTER
Fadi G Haddad, Koji Sasaki, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian
No abstract text is available yet for this article.
March 28, 2024: American Journal of Hematology
https://read.qxmd.com/read/38546371/mismatched-donor-allogeneic-hematopoietic-cell-transplantation-with-post-transplant-cyclophosphamide-achieves-comparable-outcomes-between-racially-and-ethnically-diverse-patient-populations
#3
LETTER
Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazar-Yan, Jose L Ochoa-Bayona, Hien Liu, Michael D Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A Pidala, Nelli Bejanyan, Hany Elmariah
No abstract text is available yet for this article.
March 28, 2024: American Journal of Hematology
https://read.qxmd.com/read/38546327/hydroxyurea-in-pregnancy-reframing-the-conversation
#4
EDITORIAL
Faiza Yasin, Patrick McGann, Layla Van Doren
No abstract text is available yet for this article.
March 28, 2024: American Journal of Hematology
https://read.qxmd.com/read/38534202/bleeding-self-assessments-by-patients-with-immune-thrombocytopenia-itp-an-agreement-study
#5
LETTER
Bianca Clerici, Sahrish Masood, Ishac Nazy, Ngan Tang, Madison Cranstone, Yang Liu, Milena Hadzi-Tosev, Joanne Nixon, Melanie St John, Maryam Shirinzadeh, Erin Jamula, John G Kelton, Donald M Arnold
We designed anagreement study to compare the results of bleeding assessments done in tandem by ITP patients and trained research staff. We used a modified version of the ITP Bleeding Scale, which captured the patients' worst bleeding event at any of nine anatomical sites since the time of the last assessment. Interrater agreement was determined using the 2-way kappa for the assessment of severe vs. non-severe bleeds. We analyzed 108 consecutive patients with ITP from the McMaster ITP Registry who had duplicate bleeding assessments...
March 27, 2024: American Journal of Hematology
https://read.qxmd.com/read/38526002/beam-versus-pharmacokinetics-directed-bucyvp16-conditioning-for-patients-with-peripheral-t-cell-lymphoma-undergoing-high-dose-therapy-with-autologous-hematopoietic-cell-transplantation
#6
LETTER
Robert Stuver, Agrima Mian, Samantha Brown, Sean Devlin, Paolo F Caimi, Stephanie Chinapen, Parastoo Dahi, Robert Dean, Zachary D Epstein-Peterson, Brian Hill, Steven M Horwitz, Oscar Lahoud, Richard Lin, Alison J Moskowitz, Craig Sauter, Gunjan Shah, Alison Winter, Deepa Jagadeesh, Michael Scordo
No abstract text is available yet for this article.
March 25, 2024: American Journal of Hematology
https://read.qxmd.com/read/38517255/effect-of-allogeneic-hematopoietic-stem-cell-transplantation-on-sickle-cell-disease-related-organ-complications-a-systematic-review-and-meta-analysis
#7
REVIEW
Elisabeth Dovern, Mesire Aydin, Michael R DeBaun, Komeil Alizade, Bart J Biemond, Erfan Nur
Sickle cell disease (SCD)-related organ complications are a major cause of morbidity and mortality in patients with SCD. We sought to assess whether hematopoietic stem cell transplantation (HSCT) stabilizes, attenuates, or exacerbates organ decline. We performed a systematic review and meta-analysis of trials investigating organ function before and after HSCT in patients with SCD. We searched MEDLINE/PubMed and EMBASE up to September 21, 2023. Continuous data were expressed as standardized mean difference (SMD) and pooled in a weighted inverse-variance random-effects model; binomial data were expressed as risk ratio (RR) using the Mantel-Haenszel random-effects meta-analyses...
March 22, 2024: American Journal of Hematology
https://read.qxmd.com/read/38511942/myopathy-related-to-chronic-graft-versus-host-disease-from-clinic-to-histological-immunological-characterization-by-imaging-mass-cytometry
#8
LETTER
Amélie Bourhis, Marie Robin, Stéphanie Nguyen, Arnaud Uguen, Patrice Hemon, Nathalie Dhedin, Thierry Maisonobe, Adèle de Masson, Olivier Benveniste, Gérard Socié, Régis Peffault de La Tour, Sarah Leonard-Louis, Baptiste Hervier
No abstract text is available yet for this article.
March 21, 2024: American Journal of Hematology
https://read.qxmd.com/read/38504387/benefit-of-axicabtagene-ciloleucel-versus-chemoimmunotherapy-in-older-patients-and-or-patients-with-poor-ecog-performance-status-with-relapsed-or-refractory-large-b-cell-lymphoma-after-2-or-more-lines-of-prior-therapy
#9
JOURNAL ARTICLE
Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sairah Ahmed, David B Miklos, Yi Lin, Brian T Hill, Armin Ghobadi, Sattva S Neelapu, Jason Westin, Chrisopher Dieyi, Polly Field, Harry Miao, Shilpa A Shahani, Anik Patel, Clare Spooner, Christine Fu, David Muramoto, Hairong Xu, Marcelo C Pasquini
Axicabtagene ciloleucel (axi-cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared the real-world effectiveness of axi-cel with efficacy and effectiveness of chemoimmunotherapy (CIT) in patients aged ≥65 years and patients with Eastern Cooperative Oncology Group performance status (ECOG PS) of 2. A total of 1146 patients treated with commercial axi-cel for R/R LBCL with ≥2 lines of prior therapy were included from the Center for International Blood and Marrow Transplantation Research prospective observational study, and 469 patients treated with CIT for R/R LBCL after ≥2 lines of prior therapy were included from SCHOLAR-1 (an international, multicohort, retrospective study)...
March 19, 2024: American Journal of Hematology
https://read.qxmd.com/read/38497679/hla-haploidentical-stem-cell-transplantation-in-children-with-inherited-bone-marrow-failure-syndromes-a-retrospective-analysis-on-behalf-of-ebmt-severe-aplastic-anemia-and-pediatric-diseases-working-parties
#10
JOURNAL ARTICLE
Stefano Giardino, Dirk-Jan Eikema, Brian Piepenbroek, Mattia Algeri, Mouhab Ayas, Maura Faraci, Abdelghani Tbakhi, Marco Zecca, Mohammed Essa, Bénédicte Neven, Yves Bertrand, Gaurav Kharya, Tatiana Bykova, Sarah Lawson, Mario Petrini, Alexander Mohseny, Fanny Rialland, Beki James, Anca Colita, Mony Fahd, Simone Cesaro, Ansgar Schulz, Katharina Kleinschmidt, Krzysztof Kałwak, Selim Corbacioglu, Carlo Dufour, Antonio Risitano, Régis Peffault de Latour
Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims to report the current outcomes of haplo-SCT in I-BMFs, comparing the different in vivo and ex vivo T-cell depletion approaches. One hundred and sixty-two I-BMF patients who underwent haplo-SCT (median age 7.4 years) have been registered. Fanconi Anemia was the most represented diagnosis (70...
March 18, 2024: American Journal of Hematology
https://read.qxmd.com/read/38488702/thromboembolic-risk-of-carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma-a-comparative-systematic-review-and-meta-analysis
#11
JOURNAL ARTICLE
Bruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, Nicole Felix, Carlyn Rose Tan, Neha Korde, Joshua Richter
Thrombosis represents a frequent and potentially severe complication in individuals diagnosed with multiple myeloma (MM). These events can be driven by both the disease as well as the therapies themselves. Overall, available evidence is inconclusive about the differential thrombogenicity of carfilzomib/lenalidomide/dexamethasone (KRd) and bortezomib/lenalidomide/dexamethasone (VRd). This meta-analysis compares the risk for venous thromboembolism (VTE; including deep venous thrombosis and pulmonary embolism) and arterial thromboembolism (ATE; including myocardial infarction and ischemic stroke) with KRd versus VRd as primary therapy for newly diagnosed MM (NDMM)...
March 15, 2024: American Journal of Hematology
https://read.qxmd.com/read/38488686/favorable-outcome-of-non-myeloablative-allogeneic-transplantation-in-adult-patients-with-severe-sickle-cell-disease-a-single-center-experience-of-200-patients
#12
JOURNAL ARTICLE
Moussab Damlaj, Bader Alahmari, Ahmed Alaskar, Ayman Alhejazi, Husam Alsadi, Mazin Ahmed, Tahani Alanazi, Rasha Ahmed, Amani Alharbi, Inaam Shehabeddine, Afnan Alzaidi, Suha Alkhuraisat, Isam Mahassnah, Hamza Alquraan, Maybelle Ballili, Mohsen Alzahrani
Allogeneic hematopoietic stem cell transplant (HSCT) for adults with severe sickle cell disease (SCD) is potentially curative but not commonly utilized therapy due to complications such as graft failure (GF) and organ toxicity. Herein, we are reporting our long-term outcome data of non-myeloablative (NMA) HSCT in adults with severe SCD with emphasis on factors predicting event free survival (EFS). Adults with severe SCD undergoing NMA match-related donor allogeneic HSCT from 2015 to 2021 with at least 12 months of follow-up were included...
March 15, 2024: American Journal of Hematology
https://read.qxmd.com/read/38482991/jak-inhibitor-treatment-resistant-splenomegaly-before-transplantation-in-myelofibrosis-splenectomy-or-radiotherapy
#13
EDITORIAL
Maria Chiara Finazzi, Ayalew Tefferi, Alessandro Rambaldi
No abstract text is available yet for this article.
March 14, 2024: American Journal of Hematology
https://read.qxmd.com/read/38482543/a-new-chemotherapy-free-regimen-of-olverembatinib-in-combination-with-venetoclax-and-dexamethasone-for-newly-diagnosed-ph-acute-lymphoblastic-leukemia-preliminary-outcomes-of-a-prospective-study
#14
LETTER
Hailong Tang, Weijing Jia, Shuangshuang Jia, Runan Dong, Shan Gao, Juan Feng, Hongjuan Dong, Hongtao Gu, Tao Zhang, Ruifeng Yuan, Xiangxiang Liu, Lu Cheng, Shuya Zhou, Guangxun Gao
No abstract text is available yet for this article.
March 14, 2024: American Journal of Hematology
https://read.qxmd.com/read/38481382/detection-of-signature-double-negative-t-cells-is-a-predictive-marker-to-identify-autoimmune-lymphoproliferative-syndrome-associated-with-fas-loss-of-function
#15
LETTER
Nina Eisenhauer, Maurizio Miano, Nora Naumann-Bartsch, Jörg Leyh, Gianluca Dell'Orso, Michael Aigner, Gisela Fecker, Claas Hinze, Helmut Wittkowski, Heiko Bruns, Jakob Zierk, Markus Metzler, Peter D Arkwright, Frederik Graw, Andreas Mackensen, Simon Völkl
No abstract text is available yet for this article.
March 14, 2024: American Journal of Hematology
https://read.qxmd.com/read/38476079/a-randomized-double-blind-pilot-study-to-evaluate-the-efficacy-safety-and-tolerability-of-intravenous-iron-versus-oral-iron-for-the-treatment-of-restless-legs-syndrome-in-patients-with-iron-deficiency-anemia
#16
JOURNAL ARTICLE
Vanessa Short, Richard Allen, Christopher J Earley, Huzefa Bahrain, Stella Rineer, Kiumarce Kashi, Jesse Gerb, Michael Auerbach
Restless legs syndrome (RLS) is a neurological disorder that can have a profound effect on sleep and quality of life. Idiopathic RLS is associated with brain iron insufficiency despite normal peripheral iron stores. There is, however, a five- to six-fold increase in prevalence of RLS in patients with iron deficiency anemia (IDA). Several open-label trials have demonstrated symptomatic improvement in RLS following treatment of IDA using oral or intravenous iron supplementation. To date, there have been no randomized double-blind controlled trials of intravenous iron compared with oral iron for the treatment of RLS patients with IDA...
March 13, 2024: American Journal of Hematology
https://read.qxmd.com/read/38459819/the-latest-insights-into-rare-blood-disorders-diagnosis-and-treatment-strategies
#17
REVIEW
David J Kuter, Spero R Cataland, Catherine M Broome, Cindy Neunert
Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it is essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine...
March 9, 2024: American Journal of Hematology
https://read.qxmd.com/read/38450850/chronic-myelomonocytic-leukemia-2024-update-on-diagnosis-risk-stratification-and-management
#18
JOURNAL ARTICLE
Mrinal M Patnaik, Ayalew Tefferi
DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%-20% over 3-5 years). DIAGNOSIS: Newly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 109 /L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, <20% BM or PB blasts (including promonocytes), and cytogenetic or molecular evidence of clonality...
March 7, 2024: American Journal of Hematology
https://read.qxmd.com/read/38450849/changing-hemostatic-management-in-post-partum-hemorrhage
#19
REVIEW
Agnès Rigouzzo, Pierre-Antoine Froissant, Nicolas Louvet
Early and fast assessment of hemostasis during postpartum hemorrhage (PPH) is essential to allow early characterization of coagulopathy, estimate bleeding severity and improve outcome. During PPH, fibrinogen decrease occurs earlier than other coagulation factors deficiency and hypofibrinogenemia is an early marker of PPH severity of progression. With good evidence in the context of PPH, point-of-care viscoelastic (VET) hemostatic assays have been shown to provide rapid assessment of hemostatic disorders, low fibrinogen levels, and allow VET-guided fibrinogen replacement...
March 7, 2024: American Journal of Hematology
https://read.qxmd.com/read/38450790/2024-update-on-allogeneic-hematopoietic-stem-cell-transplant-for-myelofibrosis-a-review-of-current-data-and-applications-on-risk-stratification-and-management
#20
JOURNAL ARTICLE
Haris Ali, Andrea Bacigalupo
BACKGROUND: Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed. AIMS: The aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF patients undergoing an allogeneic HSCT. METHODS: Published papers were used to analyze different aspects of allogeneic HSCT...
March 7, 2024: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.